Fireside Chat: What Will Pharma Buy Next in Pain?
4:30 pm - Thursday 28th January 2027
- Assess how recent transactions, including Lilly’s acquisitions of SiteOne Therapeutics and 4E Therapeutics, and AbbVie’s licensing agreement with Haisco Pharmaceutical for HSK21542, are reshaping partnering and investment priorities across pain
- Define the translational, clinical and commercial evidence packages required to progress from early interest to competitive deal activity
- Explore which mechanisms, indications and patient populations are attracting the strongest external interest, from NaV1.8 inhibitors and peripheral targets through to neuroimmune and disease-modifying approaches
- Identify what differentiates a partnerable pain asset today, including target validation, patient selection strategy, clinical positioning and commercial potential
